Newsroom
Our latest developments
Orca Bio’s announcements and press releases
Orca Bio to Present Clinical Data on TREGZI™ and Its Clinical Pipeline at the 14th Annual Meeting of the Society of Hematologic Oncology
ViewOrca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies
ViewOrca Bio Adds East Coast Manufacturing Capacity and Triples West Coast Manufacturing Workforce Ahead of Potential Orca-T® Launch
ViewOrca Bio Appoints Bijan Nejadnik, M.D., as Chief Medical Officer
ViewOrca Bio Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Orca-Q® for the Treatment of High-Risk Hematologic Malignancies
ViewOrca Bio Announces FDA Review Extension of BLA for Orca-T for the Treatment of Hematologic Malignancies
ViewOrca Bio to Present Clinical Data on Its Pipeline of High-Precision Cell Therapies at the 52nd Annual Meeting of the EBMT
ViewOrca Bio's fact sheets
Orca Bio Corporate Overview
View